Research programme: cancer therapeutics - BerGenBioAlternative Names: BGB 001; BGB 002 target; BGB 003; BGB 109; BGB 10C9; BGB-101
Latest Information Update: 02 Jul 2015
At a glance
- Originator BerGenBio
- Class Monoclonal antibodies; Small molecules
- Mechanism of Action Axl receptor tyrosine kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Pancreatic cancer